The Claim
IL-6 receptor blockade with tocilizumab for 3 weeks increases fasting and postprandial plasma amino acid concentrations in both healthy-weight and obese men, but does not alter skeletal muscle protein turnover.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Blocking the IL-6 receptor with tocilizumab for three weeks raises plasma amino acid levels during fasting and after meals in both healthy-weight and obese men, but does not change the rate of muscle protein synthesis or breakdown.
See the scientific wording
IL-6 receptor blockade with tocilizumab for 3 weeks increases fasting and postprandial plasma amino acid concentrations in both healthy-weight and obese men, but does not alter skeletal muscle protein turnover, indicating that basal IL-6 activity influences systemic amino acid availability without directly regulating muscle protein synthesis or degradation.
Blocking IL-6 signaling stops the liver and immune cells from pulling amino acids out of the blood, so more amino acids stay in circulation. This happens whether a person is lean or obese. The muscles don't change how much protein they make or break down, so the extra amino acids in the blood come from less uptake elsewhere, not more release from muscle.
What the research says
1 studyGiving a drug that blocks IL-6 for three weeks made more amino acids show up in the blood of both lean and obese men, but didn’t change how fast their muscles built or broke down protein — meaning IL-6 affects where amino acids go in the body, not muscle growth or loss.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.